Stockscreener 앱 받기
31.65
0.57%
-0.18
시간 외 거래:
31.40
-0.25
-0.79%
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Targets Report: How does NewAmsterdam Pharma Company NV Equity Warrant compare to its peers2025 Macro Impact & Weekly Return Optimization Plans - baoquankhu1.vn
Responsive Playbooks and the NAMSW Inflection - Stock Traders Daily
Aug Intraday: Will NewAmsterdam Pharma Company NV benefit from seasonalityJuly 2025 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Fed Meeting: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskPortfolio Return Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn
Gains Report: What is the implied volatility of Drugs Made In America Acquisition Corp Equity RightWeekly Trade Analysis & AI Enhanced Execution Alerts - baoquankhu1.vn
First Week of March 20th Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq
Relative Strength Alert For NewAmsterdam Pharma Company - Nasdaq
Aug Action: Does NewAmsterdam Pharma Company NV Equity Warrant align with a passive investing strategy2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility - Yahoo Finance
Aug Rallies: How NewAmsterdam Pharma Company NV stock compares to market leadersPortfolio Update Summary & High Return Trade Guides - Bộ Nội Vụ
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech With 46% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in NAMS Response - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.5%Time to Sell? - MarketBeat
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress - TipRanks
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative
Drug in late-stage tests cuts cholesterol and an Alzheimer’s marker - Stock Titan
Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - Улправда
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru
Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - Улправда
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock near bottom after declineAnalyst Upgrade & Verified Chart Pattern Signals - ulpravda.ru
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from strong economy2025 Historical Comparison & Community Consensus Stock Picks - Улправда
What dividend safety score for NewAmsterdam Pharma Company N.V. stock2025 Technical Patterns & Low Risk High Reward Ideas - Улправда
Louise Frederika Kooij Sells 2,647 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 6,000 Shares of Stock - MarketBeat
Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthEconomic Indicators Overview & Affordable Growth Investments - Улправда
A Look At NewAmsterdam Pharma (NAMS) Valuation As Late Stage CETP Trial Progress Draws Investor Attention - Sahm
NewAmsterdam Pharma (NAMS) Stock Analysis: Unveiling a 43.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 - Insider Monkey
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners - Investing.com Canada
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.4%Time to Sell? - MarketBeat
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS - TechStock²
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Behavioral Patterns of NAMS and Institutional Flows - Stock Traders Daily
ID Info Business Services Limited Enters Reversal Setup in Weekly ChartsEconomic Indicators Overview & Target Triple-Digit Stock Opportunities - earlytimes.in
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 75,117 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock - MarketBeat
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
How (NAMSW) Movements Inform Risk Allocation Models - Stock Traders Daily
Is NewAmsterdam Pharma Company NV Equity Warrant a good long term investmentUtilities Sector Analysis & Identify Ideal Buy Points With Precision - Early Times
EBITDA per share of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView — Track All Markets
Operating cash flow per share of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView — Track All Markets
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketMarket Growth Report & Short-Term Trading Alerts - Улправда
Analyst Downgrade: Will Lee Enterprises Incorporated LE70 stock keep raising dividendsJuly 2025 Big Picture & Precise Buy Zone Identification - moha.gov.vn
How NewAmsterdam Pharma Company N.V. Equity Warrant stock trades before earningsWeekly Investment Summary & Verified Swing Trading Watchlist - Улправда
Will NewAmsterdam Pharma Company N.V. stock deliver strong dividend growthEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterQuarterly Profit Report & Real-Time Volume Spike Alerts - Улправда
Aug Selloffs: Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Is NewAmsterdam Pharma Company N.V. stock in correction or buying zone2025 Sector Review & Reliable Breakout Forecasts - Улправда
Is NewAmsterdam Pharma Company N.V. stock undervalued vs historical averagesJuly 2025 Technicals & Daily Stock Trend Reports - DonanımHaber
Will NewAmsterdam Pharma Company N.V. stock outperform tech sector in 20252025 Earnings Surprises & Community Trade Idea Sharing - DonanımHaber
Why NewAmsterdam Pharma Company N.V. stock attracts global investorsOptions Play & Real-Time Sentiment Analysis - DonanımHaber
4.73%
0.92%
자본화:
|
볼륨(24시간):